Literature DB >> 24452997

Antidepressant drugs and the risk of suicide in children and adolescents.

Göran Isacsson1, Charles L Rich.   

Abstract

Government agencies have issued warnings about the use of antidepressant medications in children, adolescents, and young adults since 2003. The statements warn that such medications may cause de novo 'suicidality' in some people. This review explores the data on the treatment of depression that led to these warnings and subsequent data that are relevant to the warnings. It also addresses the effectiveness of antidepressant treatment in general and the relationship of suicide rates to antidepressant treatment. It concludes that the decisions for the 'black box' warnings were based on biased data and invalid assumptions. Furthermore, the decisions were unsupported by the observational data regarding suicide in young people that existed in 2003. The following recommendations would seem to follow from these observations. First, drug authorities should re-evaluate the basis for their imposed warnings on antidepressant medicines, and analyze the actual public health consequences the warnings have had. In the absence of substantial evidence supporting the warnings, they should be removed. Second, physicians and other providers with prescription privileges should continue to be educated regarding the importance of aggressively treating depression in young people, using antidepressants when indicated. Third, physicians and other professionals who treat depressed young people must always be aware of the risk of suicide (albeit quite low) and observe them closely for any signs of increased risk of suicide. This is necessary regardless of the type of treatment being provided.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24452997     DOI: 10.1007/s40272-013-0061-1

Source DB:  PubMed          Journal:  Paediatr Drugs        ISSN: 1174-5878            Impact factor:   3.022


  46 in total

1.  Suicide prevention--a medical breakthrough?

Authors:  G Isacsson
Journal:  Acta Psychiatr Scand       Date:  2000-08       Impact factor: 6.392

2.  Suicidal thoughts and behavior with antidepressant treatment: reanalysis of the randomized placebo-controlled studies of fluoxetine and venlafaxine.

Authors:  Robert D Gibbons; C Hendricks Brown; Kwan Hur; John Davis; J John Mann
Journal:  Arch Gen Psychiatry       Date:  2012-06

3.  Selective serotonin reuptake inhibitor antidepressants and the risk of suicide: a controlled forensic database study of 14,857 suicides.

Authors:  G Isacsson; P Holmgren; J Ahlner
Journal:  Acta Psychiatr Scand       Date:  2005-04       Impact factor: 6.392

4.  Selection criteria and generalizability within the counterfactual framework: explaining the paradox of antidepressant-induced suicidality?

Authors:  Herbert I Weisberg; Vanessa C Hayden; Victor P Pontes
Journal:  Clin Trials       Date:  2009-04       Impact factor: 2.486

5.  Antidepressant drug use and suicide prevention.

Authors:  Göran Isacsson; Charles L Rich
Journal:  Int Rev Psychiatry       Date:  2005-06

Review 6.  ACNP Task Force report on SSRIs and suicidal behavior in youth.

Authors:  J John Mann; Graham Emslie; Ross J Baldessarini; William Beardslee; Jan A Fawcett; Frederick K Goodwin; Andrew C Leon; Herbert Y Meltzer; Neal D Ryan; David Shaffer; Karen D Wagner
Journal:  Neuropsychopharmacology       Date:  2006-03       Impact factor: 7.853

7.  The relationship between antidepressant prescription rates and rate of early adolescent suicide.

Authors:  Robert D Gibbons; Kwan Hur; Dulal K Bhaumik; J John Mann
Journal:  Am J Psychiatry       Date:  2006-11       Impact factor: 18.112

8.  Fluoxetine, cognitive-behavioral therapy, and their combination for adolescents with depression: Treatment for Adolescents With Depression Study (TADS) randomized controlled trial.

Authors:  John March; Susan Silva; Stephen Petrycki; John Curry; Karen Wells; John Fairbank; Barbara Burns; Marisa Domino; Steven McNulty; Benedetto Vitiello; Joanne Severe
Journal:  JAMA       Date:  2004-08-18       Impact factor: 56.272

9.  Persisting decline in depression treatment after FDA warnings.

Authors:  Anne M Libby; Heather D Orton; Robert J Valuck
Journal:  Arch Gen Psychiatry       Date:  2009-06

10.  Decline in treatment of pediatric depression after FDA advisory on risk of suicidality with SSRIs.

Authors:  Anne M Libby; David A Brent; Elaine H Morrato; Heather D Orton; Richard Allen; Robert J Valuck
Journal:  Am J Psychiatry       Date:  2007-06       Impact factor: 18.112

View more
  8 in total

Review 1.  Pediatric inflammatory bowel disease and depression: treatment implications.

Authors:  Divya Keethy; Christine Mrakotsky; Eva Szigethy
Journal:  Curr Opin Pediatr       Date:  2014-10       Impact factor: 2.856

2.  Safety of 80 antidepressants, antipsychotics, anti-attention-deficit/hyperactivity medications and mood stabilizers in children and adolescents with psychiatric disorders: a large scale systematic meta-review of 78 adverse effects.

Authors:  Marco Solmi; Michele Fornaro; Edoardo G Ostinelli; Caroline Zangani; Giovanni Croatto; Francesco Monaco; Damir Krinitski; Paolo Fusar-Poli; Christoph U Correll
Journal:  World Psychiatry       Date:  2020-06       Impact factor: 49.548

Review 3.  Is Transcranial Magnetic Stimulation Appropriate For Treating Adolescents with Depression?

Authors:  Puneet Narang; Katelyn Madigan; Simrat Sarai; Steven Lippmann
Journal:  Innov Clin Neurosci       Date:  2019-09-01

4.  Toxoplasmosis Titers and past Suicide Attempts Among Older Adolescents Initiating SSRI Treatment.

Authors:  William Coryell; Robert Yolken; Brandon Butcher; Trudy Burns; Lilian Dindo; Janet Schlechte; Chadi Calarge
Journal:  Arch Suicide Res       Date:  2016-04-04

5.  Rho-kinase inhibition has antidepressant-like efficacy and expedites dendritic spine pruning in adolescent mice.

Authors:  Lauren P Shapiro; Henry W Kietzman; Jidong Guo; Donald G Rainnie; Shannon L Gourley
Journal:  Neurobiol Dis       Date:  2018-12-26       Impact factor: 5.996

6.  Existence of Notoriety Bias in FDA Adverse Event Reporting System Database and Its Impact on Signal Strength.

Authors:  Reddy Neha; Viswam Subeesh; Elsa Beulah; Nair Gouri; Eswaran Maheswari
Journal:  Hosp Pharm       Date:  2019-10-18

Review 7.  Neurobiological Basis of Increased Risk for Suicidal Behaviour.

Authors:  Aleksandra Wisłowska-Stanek; Karolina Kołosowska; Piotr Maciejak
Journal:  Cells       Date:  2021-09-23       Impact factor: 6.600

Review 8.  Pediatric Narcolepsy-A Practical Review.

Authors:  I-Hang Chung; Wei-Chih Chin; Yu-Shu Huang; Chih-Huan Wang
Journal:  Children (Basel)       Date:  2022-06-29
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.